Clinical trials: Rectal Cancer, Radiotherapy
Rectal Neoplasms
Watch and Wait as Treatment for Patients With Rectal Cancer
A national cohort study with all patients scheduled for neoadjuvant treatment with (chemo)radiotherapy or short course radiotherapy with delayed surgery 6-8 weeks) for rectal cancer staged as cT4bNX/anycTanycN and…
- Trial name
- WoW (NCT03125343)
- Testing
- endoscopy, Surgery, MRI
- Where
- 2 sites in Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Locally Advanced Rectal Cancer
Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer
This is a single arm, open-label, prospective phase II clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and immunotherapy (PD-1 antibody) for patients with locally advanced rectal cancer (LARC).
- Trial name
- NCT04663763
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Prostate Cancer, Cancer
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
To effectively treat prostate cancer, doctors need an accurate view (via X-rays) of the prostate gland during radiation therapy.
- Trial name
- NCT00061347
- Testing
- Fiducial marker placement
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Radiation-induced Intestinal Injury
Prediction of the Chronicization of Radiation-induced Acute Intestinal Injury
Our team has constructed a prediction model based on the expression level of immune factors (PD-L1, PD-1, CTLA4, Siglec15) to predict the chronicization of radiation-induced acute intestinal injury (RAII) and verified the…
- Trial name
- CRAII (NCT05749484)
- Testing
- NCRT+TME
- Volunteers
- 200 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
Low and Intermediate Risk OliGometastatic ColoREctal CancEr PatieNts Treated with Stereotactic ABlative Radiotherapy
This is an experimental study without drug or device, randomized, open-label, non-profit, sponsored by the IRCCS Sacro Cuore Don Calabria Hospital in Negrar, which will take place at the Department of Advanced Oncological…
- Trial name
- GREENLaIT-SABR (NCT06310564)
- Testing
- SABR
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Rectal Cancer, Radiotherapy
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer
This is a prospective, single-arm, biomarker-stratified, multicenter phase 2 clinical trial. All enrolled patients first receive short-course radiotherapy (SCRT), followed by measurement of serum β-hydroxybutyrate (β-HB) levels…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
- Trial name
- NCT07847229
- Testing
- Short-course radiotherapy, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Tao Zhang
Rectal Cancer
A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy.
- Trial name
- NCT01269229
- Testing
- folfox, short course Radiotherapy
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Rectal Cancer
Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer
The purpose of this study is to establish the influence of time-interval between preoperative hyperfractionated radiotherapy (5x5 Gy) and surgery on long term overall survival (5 years), local and distant recurrence rate…
- Trial name
- NCT01444495
- Testing
- Preoperative radiotherapy, Surgery
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Jagiellonian University
Stomach Cancer, Gall Bladder Cancer
Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
The purpose with this study is to evaluate treatment with radio chemotherapy (oxaliplatin and capecitabine) given concommitant with radiotherapy in patients with gastrointestinal tumors.
- Conditions
- Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer
- Trial name
- CORGI (NCT01016639)
- Testing
- oxaliplatin, capecitabine, radiotherapy
- Where
- 5 sites in Sweden
- Volunteers
- 106 people
- Sponsor
- Lund University Hospital
Rectal Cancer
Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study
INTERACT study: to evaluate the pathological response rate in cT3 rectal cancer LEADER study: to evaluate the impact on local control of local excision
- Trial name
- INTERACT (NCT01653301)
- Testing
- XELAC RT, XELOX RT
- Where
- Italy
- Volunteers
- 616 people
- Sponsor
- Catholic University of the Sacred Heart
Colorectal Cancer
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy
- Trial name
- NCT06516445
- Testing
- SCRT, Camrelizumab, Fluzoparib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Huazhong University of Science and Technology
Locally Advanced Rectal Cancer
Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study
The use of preoperative chemoradiation and adjuvant chemotherapy with 5-FU based chemotherapy reduced local recurrence rate to less than 10%, but has only had limited effect on overall survival due to the constantly high (more…
- Trial name
- CRAB (NCT00842686)
- Testing
- bevacizumab, capecitabine
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- Institute of Oncology Ljubljana
Rectum Cancer, Adenocarcinoma
Adaptive Radiation Boost for Rectal Cancer
The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.
- Trial name
- ARBOR (NCT07221058)
- Testing
- Adaptive Radiotherapy Boost
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Rectal Neoplasms
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
Improvements in downstaging are required when using preoperative chemoradiation for unresectable rectal cancer. There is therefore a need to explore more effective schedules.
- Trial name
- SUNRISE (NCT03714490)
- Testing
- SCPRT, CRT, CAPOX
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00392470
- Testing
- cetuximab, irinotecan hydrochloride, conventional surgery
- Where
- 3 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Locally Advanced Rectal Cancer, Rectal Adenocarcinoma
Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer
This prospective national multicentre feasibility study evaluates dose-escalated short-course proton radiotherapy followed by total neoadjuvant chemotherapy in patients with primary high-risk locally advanced rectal…
- Trial name
- PROSPECT-WW (NCT07903883)
- Testing
- Intensity modulated proton therapy
- Where
- 8 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Colorectal Cancer
Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27
The purpose of this study is: Evaluation of the safety and effectiveness of the Compression Anastomosis Ring (CAR™ 27) device for creation of circular, colorectal anastomoses in previously radiated patients.
- Trial name
- NCT01056796
- Testing
- CAR™ 27
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Niti Medical Technologies Ltd.
Rectal Cancer
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab (Avastin) and erlotinib hydrochloride (Tarceva) that can be given in combination with standard radiation therapy and capecitabine…
- Trial name
- NCT00543842
- Testing
- Bevacizumab, Capecitabine, Erlotinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Radiotherapy Induced Diarrhea, Acute Radiation Enteritis
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation.
- Conditions
- Radiotherapy Induced Diarrhea, Acute Radiation Enteritis, Prostate Cancer, Cervical Adenocarcinoma
- Trial name
- NCT06783153
- Testing
- Rifaximin 550 MG, Standard Care Chemoradiation
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Mansoura University